Patents by Inventor Wengeng LIU

Wengeng LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BTK INHIBITORS
    Publication number: 20230122807
    Abstract: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, of the formula (I) which possess BTK inhibitory activity and are accordingly useful in therapy and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them, and to their use in the manufacture of medicaments for use in a therapeutic effect in a warm-blooded animal such as man.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 20, 2023
    Inventors: Quan ZHOU, Changmao SHEN, Xiang CHEN, Wengeng LIU, Rumin WANG, Qingbei ZENG, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • ErbB/BTK inhibitors
    Patent number: 11504375
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: November 22, 2022
    Assignee: DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
    Inventors: Zhengtao Li, Hao Zou, Wei Zhu, Changmao Shen, Rumin Wang, Wengeng Liu, Xiang Chen, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • ERBB/BTK INHIBITORS
    Publication number: 20210252005
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    Type: Application
    Filed: April 7, 2021
    Publication date: August 19, 2021
    Inventors: Zhengtao LI, Hao ZOU, Wei ZHU, Changmao SHEN, Rumin WANG, Wengeng LIU, Xiang CHEN, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • ErbB/BTK inhibitors
    Patent number: 11007198
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: May 18, 2021
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Zhengtao Li, Hao Zou, Wei Zhu, Changmao Shen, Rumin Wang, Wengeng Liu, Xiang Chen, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • ERBB/BTK INHIBITORS
    Publication number: 20200316079
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Inventors: Zhengtao LI, Hao ZOU, Wei ZHU, Changmao SHEN, Rumin WANG, Wengeng LIU, Xiang CHEN, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG